Why the study?
Does concomitant administration of cerivastatin and risperidone induce rhabdomyolysis?
Does concomitant administration of cerivastatin and risperidone induce rhabdomyolysis?
Risperidone may induce statin toxicity, such as severe rhabdomyolysis, when coadministered with cerivastatin, likely due to competitive inhibition of the CYP3A4 pathway.
Answers are grounded in this paper and cite their sources.
May warrant vigilance for statin-risperidone interaction in rhabdomyolysis; hypothesis-generating and requires prospective confirmation before practice change.
DEAR SIR The toxicity related with the concomitant administration of statins and fibrates, nicotinic acid, erythromycin, HIV-inhibitor proteases, cyclosporin and antifungals has been described. This interaction is mainly attributable to inhibition of statins in liver metabolism. All the statins, except fluvastatin, are mainly metabolized by CYP-450 3A4 isoenzyme, with only cerivastatin undergoing a double CYP-450 pathway by 2C8 and 3A4 isoenzymes [1, 2]. Because of its double metabolism, cerivastatin has been considered with a lower propensity for drug interactions [3]. Risperidone, a new antipsychotic, is also metabolized through a double CYP-450 pathway by 3A4 and 2D6 isoenzymes [4]. We describe the case of a severe cerivastatin-induced rhabdomyolysis in a patient simultaneously treated with risperidone and cerivastatin. A 69-year-old woman (body mass index: 37 kg m−2) with hypercholesterolemia, essential hypertension and dysthymic disorder was admitted to the hospital because of a painful progressive muscle weakness that began 6 months earlier. The legs were initially affected with progressive invalidating walking impairment, eventually requiring bed-restriction. Arms were progressively affected during the sixth month. The patient had been treated with risperidone (6 mg day−1), biperiden (2 mg day−1), lormetazepam (6 mg day−1) and nifedipine (30 mg day−1) for more than 2 years. She was also treated sequentially with gemfibrozil (600 mg day−1), then pravastatin (20 mg day−1) and, 1 month before the onset of symptoms, cerivastatin (0.2–0.4 mg day−1) on alternating days. Physical examination showed flaccid paraplegia and paresia 3/5 in upper extremities, and tenderness to muscle pressure. Laboratory studies revealed aspartate aminotransferase (AST, 4.91 μkat L−1), alanine aminotransferase (ALT, 5.50 μkat L−1) (normal values for both, 0–0.58 μkat L−1) and creatine kinase (CK, 291.05 μkat L−1) (normal value, 0.25–1.50 μkat L−1). The patient developed progressive clinical and analytical improvement after withdrawal of all drugs. Because of psychiatric symptoms, risperidone (4.5 mg/24 h), lormetazepam (3 mg/24 h) and lorazepam (2 mg/24 h) were reintroduced. Forty-eight hours later the patient developed right hyponcondrial pain with AST (5.95 μkat L−1), ALT (4.25 μkat L−1) and CK (1.17 μkat L−1). Liver echography was normal, with fine needle aspiration showing toxic hepatitis. Serologies for hepatitis virus A, B and C were negative. After risperidone withdrawal analytical impairment disappeared. One month after admission the patient was discharged with a minimal walking impairment, and 1 year later she had totally recovered in the absence of risperidone and statins. The chronological correlation allows to relate the rhabdomyolysis of the patient with the coadministration of cerivastatin and risperidone, as previously reported with gemfibrozil [5] and cyclosporin [6]. In the presence of a poor metabolizer of debrisoquine/sparteine, a polymorphic form of CYP 2D6 present in 10% of the population, risperidone undergoes minor metabolism by this isoenzyme [2, 4]. If our patient possesses this polymorphism, the deviation of risperidone metabolism to CYP3A4 pathway could result in decreased cerivastatin metabolism by means of a competitive mechanism. A decreased metabolism of cerivastatin secondary to risperidone hepatotoxicity is also possible, probably immunologically mediated taking into account the rapid evolution [7]. The absence of toxicity when the patient was treated with pravastatin, the unique statin with an independent CYP-450 liver metabolism [1, 2], makes the first of our hypotheses the more likely. This case strongly suggests that risperidone should be added to the list of substances that could induce statins toxicity.
No takes yet. Share an insight, caveat, or question.
Giner et al. (2002) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: